Published in
Elsevier, Journal of Investigative Dermatology, 10(142), p. 2651-2659.e1, 2022
DOI: 10.1016/j.jid.2022.03.029
Links
Tools
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial
Journal article published in 2022 by
Victoria P. Werth 
,
Emily Hejazi ,
Sandra M. Pena ,
Jessica Haber ,
Majid Zeidi ,
Nithin Reddy ,
Joyce Okawa ,
Rui Feng ,
Muhammad M. Bashir ,
Kirubel Gebre ,
Arvin S. Jadoo ,
Josef Symon S. Concha ,
Nancy Dgetluck ,
Scott Constantine ,
Barbara White
,
Emily Hejazi ,
Sandra M. Pena ,
Jessica Haber ,
Majid Zeidi ,
Nithin Reddy ,
Joyce Okawa ,
Rui Feng ,
Muhammad M. Bashir ,
Kirubel Gebre ,
Arvin S. Jadoo ,
Josef Symon S. Concha ,
Nancy Dgetluck ,
Scott Constantine ,
Barbara White
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 